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Abstract
Background: Obesity at diagnosis is associated with poor prognosis in women with breast cancer, but few reports have been
adjusted for treatment factors.

article

Methods: CALGB 9741 was a randomized trial of dose density and sequence of chemotherapy for node-positive breast
cancer. All patients received doxorubicin, cyclophosphamide, and paclitaxel, dosed by actual body weight. Height and
weight at diagnosis were abstracted from patient records, and the PAM50 assay was performed from archived specimens
using the NanoString platform. Relationships between body mass index (BMI), PAM50, and recurrence-free and overall
survival (RFS and OS) were evaluated using proportional hazards regression, adjusting for number of involved nodes,
estrogen receptor (ER) status, tumor size, menopausal status, drug sequence, and dose density. All statistical tests were twosided.
Results: Baseline height and weight were available for 1909 of 2005 enrolled patients; 1272 additionally had subtype
determination by PAM50. Median baseline BMI was 27.4 kg/m2. After 11 years of median follow-up, there were 619 RFS
events and 543 deaths. Baseline BMI was a statistically significant predictor of RFS (adjusted hazard ratio [HR] for each fiveunit increase in BMI = 1.08, 95% confidence interval [CI] = 1.02 to 1.14, P = .01) and OS (adjusted HR = 1.08, 95% CI = 1.01 to
1.14, P = .02) BMI and molecular phenotypes were independent prognostic factors for RFS, with no statistically significant
interactions detected.
Conclusions: BMI at diagnosis was a statistically significant prognostic factor in a group of patients receiving optimally
dosed chemotherapy. Additional research is needed to determine the impact of weight loss on breast cancer outcomes and
to evaluate whether this impact is maintained across tumor subtypes.

Obesity is a well-established risk factor for poor prognosis in
women with early-stage breast cancer (1–4). Several reviews
and meta-analyses have summarized the many studies looking

at the relationship between body weight at the time of breast
cancer diagnosis and cancer outcomes in women with earlystage disease. For example, a recent meta-analysis of 82 reports
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on this topic reported a 34% increase in breast cancer–related
mortality and a 41% increase in overall mortality in women who
were obese at the time of breast cancer diagnosis as compared
with women who were of normal weight (4).
Some controversy exists regarding the interaction between
tumor hormone receptor status and the relationship between
body weight and breast cancer prognosis. A recent report from
the Early Breast Cancer Trialists Group evaluating the relationship between body mass index (BMI) at diagnosis and breast
cancer mortality in women with early-stage breast cancer
participating in adjuvant therapy trials demonstrated a 34%
increase in breast cancer mortality in obese premenopausal
women with hormone receptor–positive cancer, but did not
show any relationship between body weight and outcomes in
women with hormone receptor–negative cancers (5). In contrast,
a meta-analysis of 21 studies found no evidence of interaction
by hormone receptor status on the relationship between obesity
and outcomes (6).
The mechanisms underlying the relationship between BMI
and prognosis in early breast cancer are not fully understood.
Some reports have suggested that part of this excess in breast
cancer mortality in obese women may arise because of differences in tumor biology, with obese women being more likely
to develop high-grade or hormone receptor–negative tumors
(7,8). Other work has focused on the role of treatment factors
in mediating the relationship between body weight and cancer outcomes, given that obese patients have often received
less aggressive or dose-reduced therapy in the adjuvant setting
(9,10). Finally, translational work has demonstrated that metabolic hormones and inflammatory mediators are linked to both
obesity and breast cancer outcomes (11–14), suggesting putative
pathways through which host factors could influence cancer
growth and progression.
In order to overcome the adverse impact of obesity on outcomes in early breast cancer, a better understanding of the factors driving the relationship between body weight and breast
cancer outcomes is needed. We evaluated the relationship
between body mass index and rates of breast cancer recurrence
and all-cause mortality in patients who participated in Cancer
and Leukemia Group B (CALGB) 9741, an adjuvant treatment
trial for women with breast cancer that required weight-based
dosing for all participants, regardless of BMI (15). Additionally,
we evaluated the relationship between BMI and distribution of
tumor subtypes, in order to provide better insight into whether
obese patients developed tumors that were biologically more
aggressive. Finally, given the conflicting data regarding the
interaction between tumor hormone receptor status and the
relationship between body weight and breast cancer prognosis,
we explored the relationships among tumor subtype, BMI, and
cancer recurrence.

Height and weight at the time of participant enrollment (after
definitive surgery but before initiation of systemic therapy)
were abstracted from patient study charts stored at the Alliance
Statistics and Data Center. BMI was calculated according to
the formula: BMI = weight (kg)/height (m)2. BMI categories were
defined according to the World Health Organization as underweight (<18.5 kg/m2), normal weight (18.5–24.9 kg/m2), overweight (25–29.9 kg/m2), and obese (BMI ≥ 30 kg/m2).
Verification of chemotherapy dosing was performed to ensure
that overweight and obese patients received adequate doses of
protocol therapy. Assessment of chemotherapy dose delivery
was based upon cycle 1 doxorubicin administration tested as a
dichotomous variable, with adequate delivery defined as receipt
of as at least 95% of the expected dose. Expected dose was calculated according to the body surface area reported by the study
site at the time of patient enrollment.
PAM50 subtype was assessed using paraffin-embedded
archived tumor tissue for all patients from whom tissue was
available. RNA extraction from either block punches or macrodissected slides was performed at Washington University
Clinical Laboratory Improvement Amendment (CLIA) molecular
laboratories using an isolation kit and procedures provided by
NanoString Technologies, Inc., and expression profiles were generated on a Research Use Only (RUO) nCounter Analysis System
and RUO PAM50 probe set. Raw data (RCC files) that passed sample and quality metrics were provided in a blinded fashion to
NanoString Technologies for normalization and analysis with
a proprietary PAM50 algorithm. Gene expression profiles were
categorized using a four-level classifier: Luminal A, Luminal B,
Basal-like, and HER2-enriched, based upon Pearson’s distance to
centroids reestablished for the nCounter platform.

Methods

Statistical Analysis

The patient cohort for this study was taken from the study population of C9741 (15), a randomized trial testing the impact of
chemotherapy drug sequence and dose density upon the risk of
cancer recurrence in women with lymph node–positive breast
cancer. All patients in C9741 received treatment with cyclophosphamide, doxorubicin, and paclitaxel. The study used a
two-by-two factorial design. The first factor was drug sequence
(concurrent doxorubicin and cyclophosphamide followed by
paclitaxel vs doxorubicin, followed by paclitaxel followed by
cyclophosphamide), and the second factor was dose-density
(treatment cycles every two weeks with growth factor support

Data collection and statistical analyses were conducted by the
Alliance Statistics and Data Center. Descriptive statistics were
used to summarize baseline BMI. Comparisons between patient
and tumor characteristics and BMI categories were tested using
the Mann-Whitney test and Pearson chi-squared test for continuous and categorical variables, respectively. The primary endpoint was recurrence-free survival (RFS) under the STEEP system
(16), defined as time from study entry until first recurrence,
whether local or distant, or death without recurrence. Patients
who were alive and recurrence free were censored at the date of
last status verification. Contralateral breast cancers and second

vs every three weeks). The study protocol mandated that all
chemotherapy be dosed by actual body weight. The protocol
suggested a five-year course of tamoxifen for all premenopausal
women with estrogen receptor–positive breast cancer and for all
postmenopausal women regardless of hormone receptor status.
Eligibility criteria included the presence of at least one involved
lymph node, absence of metastatic cancer, and diagnosis of
breast cancer within the past 84 days.
The study was open to enrollment between September 1997
and March 1999. The CALGB, Eastern Cooperative Oncology
Group, Southwest Oncology Group, and North Central Cancer
Treatment Group participated in the study (CALGB is now part
of the Alliance for Clinical Trials in Oncology). All participants
signed an institutional review board–approved, protocol-specific
informed consent document meeting all federal and institutional regulatory requirements.

article

Measures

3 of 7

|

JNCI J Natl Cancer Inst, 2015, Vol. 107, No. 9

primary non-breast cancers were not considered failures; participants continued to be followed for RFS. With 1909 patients
and 552 RFS events anticipated, there was 90% power to observe
a hazard ratio of 1.32 under a median split of BMI when using a
two-sided alpha of 0.05 for testing. Overall survival (OS), defined
as time from study entry until death because of any cause, was

a secondary study endpoint. Distributions of RFS and OS were
calculated using the Kaplan-Meier product limit method.
The relationship between BMI and RFS was first explored
in a proportional hazards regression model using nonlinear cubic spline functions knotted at evenly spaced quintiles
(see Supplementary Figure 1, available online), and linear and

Table 1. Patient characteristics by baseline body mass index
BMI category

P*
Characteristic

article

Study patients
Study patients
Drug sequence
Sequential
Concurrent
Dose density
3 weeks
2 weeks
Age, y
20–29
30–39
40–49
50–59
60–69
(Median)
Ethnicity
White
Hispanic
African Amer
Asian
Other
Not reported
Menopausal
Pre
Post
Tumor size, cm
At most 2
>2 but ≤5
Missing
No. positive nodes
1–3
4–9
10+
Missing
ER status
Negative
Positive
Missing
PgR status
Negative
Positive
Missing
Tamoxifen use
Yes
No
Missing

Underweight
(<18.5 kg/m2)

Normal
(18.5–24.9 kg/m2)

Overweight
(25–29.9 kg/m2)

Obese
(≥30 kg/m2)

Total

No. (%)

No. (%)

No. (%)

No. (%)

No. (%)

22 (1.1)
22 (100)

623 (32.6)
623 (100)

628 (32.9)
628 (100)

636 (33.3)
636 (100)

1909 (100)
1909 (100)

12 (54.5)
10 (45.5)

307 (49.3)
316 (50.7)

293 (46.7)
335 (53.3)

332 (52.2)
304 (47.8)

944 (49.4)
965 (50.6)

9 (40.9)
13 (59.1)

328 (52.6)
295 (47.4)

307 (48.9)
321 (51.1)

311 (48.9)
325 (51.1)

955 (50.0)
954 (50.0)

4 (18.2)
8 (36.4)
5 (22.7)
4 (18.2)
1 (4.5)
(50)

126 (20.2)
241 (38.7)
178 (28.6)
65 (10.4)
13 (2.1)
(48)

98 (15.6)
199 (31.7)
204 (32.5)
107 (17.0)
20 (3.3)
(51)

63 (9.9)
216 (34.0)
233 (36.6)
109 (17.1)
15 (2.4)
(51)

291 (15.2)
664 (34.8)
620 (32.5)
285 (14.9)
49 (2.6)
(50)

20 (90.9)
0 (0)
2 (9.1)
0 (0)
0 (0)
0 (0)

540 (86.7)
17 (2.7)
34 (5.5)
20 (3.2)
11 (1.8)
1 (0.2)

517 (82.3)
30 (4.8)
71 (11.3)
6 (1.0)
4 (0.6)
0 (0)

494 (77.7)
33 (5.2)
98 (15.4)
2 (0.3)
8 (1.3)
1 (0.2)

1571 (82.3)
80 (4.2)
205 (10.7)
28 (1.5)
23 (1.2)
2 (0.1)

10 (45.5)
12 (54.5)

364 (58.4)
259 (41.6)

304 (48.4)
324 (51.6)

272 (42.8)
364 (57.2)

950 (49.8)
959 (50.2)

6 (27.3)
16 (72.7)
0 (0)

288 (46.2)
322 (51.7)
13 (2.1)

240 (38.2)
371 (59.1)
17 (2.7)

226 (35.5)
396 (62.3)
14 (2.2)

760 (39.8)
1105 (57.9)
44 (2.3)

13 (59.1)
7 (31.8)
2 (9.1)
0 (0)

394 (63.2)
171 (27.4)
53 (8.5)
5 (0.8)

369 (58.8)
184 (29.3)
68 (10.8)
7 (1.1)

364 (57.2)
185 (29.1)
82 (12.9)
5 (0.8)

1140 (59.7)
547 (28.7)
205 (10.7)
17 (0.9)

8 (36.5)
14 (63.6)
0 (0)

216 (34.7)
400 (64.2)
7 (1.1)

204 (32.5)
412 (65.6)
12 (1.9)

211 (33.2)
410 (64.5)
15 (2.4)

639 (33.5)
1236 (64.7)
34 (1.8)

11 (50.0)
10 (45.5)
1 (4.5)

255 (40.9)
357 (57.3)
11 (1.8)

260 (41.4)
352 (56.1)
16 (2.5)

260 (40.9)
361 (56.8)
15 (2.4)

786 (41.2)
1080 (56.6)
43 (2.3)

16 (72.7)
6 (27.3)
0 (0)

429 (68.9)
185 (29.7)
9 (1.4)

464 (73.9)
159 (25.3)
5 (0.8)

438 (68.9)
186 (29.2)
12 (1.9)

1347 (70.6)
532 (27.9)
26 (1.4)

.25

.38

<.001†

<.001‡

<.001

.004

.44

.71

.87

.30

* P value is from comparison of stated variable and body mass index category using a Pearson chi-squared test. Unless otherwise stated, comparisons are by specified
categories. BMI = body mass index; ER = estrogen receptor; PgR = progestin receptor.
† Age as a continuous variable.
‡ Comparison of white vs all other ethnicities.
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nonlinear BMI components were assessed using Wald-type tests
(17). Next, multivariable proportional hazards regression models
(18) evaluated the adjusted hazard ratio of RFS (and OS) for a linear increase of pretreatment BMI when including study factors
(sequence of chemotherapeutic regimen [sequential vs concurrent] and cycle length [q2-week vs q3-week]) as well as patient/
tumor characteristics of documented importance in early-stage
breast cancer: estrogen receptor (ER) status (negative vs positive),
tumor size (square root transformation), menopausal status (pre
vs post) and number of positive lymph nodes (square root transformation). PAM50-intrinsic subtypes were evaluated as a fourlevel factor. Interactions between BMI and PAM50 subtype and
between BMI and ER were tested in the multivariable model of
RFS described above. The assumption of proportional hazards was
evaluated using the methods from Grambsch and Therneau (19).
Adjusted hazard ratios from multivariable models are reported
with 95% confidence intervals and Wald-type P values. A P value of
less than .05 was considered statistically significant. All statistical
inferences were performed using SAS v9.2 (Cary, NC) or R v3.1.1(20).

Overweight and obese women were more likely to be nonwhite
(20.0% vs 14.3%) and postmenopausal (54.4% vs 41.4%) and more
likely to have tumors bigger than 2 cm (63.1% vs 52.4%) compared with normal and underweight women. There was no relationship between BMI and number of involved nodes. BMI was
not associated with estrogen or progesterone receptor status.
In the subgroup with tissue available for the PAM50 assessment (n = 1272), there was a moderate difference in the distribution of subtypes by BMI category (P = .03) (Table 2). The proportions
of tumors that were Basal-like and HER2-enriched were generally similar across weight groups. In contrast, although the
overall frequency of Luminal tumors was similar across weight
groups, the proportion of Luminal tumors that were Luminal B
was greater in obese women (52.2%) relative to overweight and
normal weight women (44.7% and 37.9%, respectively).

BMI and Chemotherapy Dose Delivery
Dosing information was available for 1786 patients. Almost all
patients received more than 95% of expected dose delivery for the
first cycle of doxorubicin protocol therapy, with only 1.9% of patients
receiving reduced doses of doxorubicin for the first cycle of treatment. There was no difference between the proportion of patients
who received reduced-dose therapy by BMI category, with 1% of normal weight, 2% of overweight, and 3% of obese individuals receiving
reduced doses of therapy for the first treatment cycle (P = .22).

Results
Two thousand five individuals were enrolled in C9741, 1972 of
whom initiated protocol treatment (see Supplementary Figure 2,
available online). Primary study results have been published previously by Citron et al. (15). In brief, patients randomly assigned
to every-two-week therapy experienced a statistically significant
improvement in recurrence-free survival and overall survival as
compared with those randomly assigned to every-three-week
therapy (HR = 0.74, 95% CI = 0.59 to 0.93, P = .01 and HR = 0.69,
95% CI = 0.50 to 0.93, P = .01 for RFS and OS, respectively). There
was no difference in outcomes between patients randomly
assigned to concurrent vs sequential therapy.
Baseline BMI was available for 1909 of 2005 patients. These
patients comprise the study sample for the current analysis. Of
these patients, 1272 had PAM50 subtyping results available and
comprise the sample for the PAM50 subset analyses. Baseline
characteristics of the 1909 patients for whom pretreatment BMI
was available are presented in Table 1. Half of the participants were
premenopausal, 64.7% had estrogen receptor–positive tumors,
59.7% had one to three involved nodes, 57.9% had tumors between
2 and 5 cm, and 70.6% took tamoxifen. Median BMI was 27.4 kg/m2
(range 16.1–74.8); 1.1% of patients were underweight, 32.6% were
normal weight, 32.9% were overweight, and 33.3% were obese.

At a median follow up of 11 years (range = 2–13 years), there
were 619 RFS events and 543 deaths among the 1909 patients for
whom baseline BMI was available. The univariate relationship
between baseline BMI category and RFS is shown in Figure 1. In
univariate analysis with spline regression models, a linear relationship between BMI and RFS was statistically significant (P <
.04), while nonlinear components of the model did not reach
nominal statistical significance (all Ps > .4) (Supplementary
Figure 1, available online). This supported considering BMI as a
linear term in the regression models. In multivariable analyses
adjusted for number of involved lymph nodes, tumor size, estrogen receptor status, menopausal status of the patient, and treatment arm, baseline BMI was a statistically significant predictor
of RFS (P = .01) (Table 3). In this multivariable model, a five-unit
increase in BMI corresponded to an 8% increase in risk of an RFS
event (adjusted HR = 1.08, 95% CI = 1.02 to 1.14, P = 0.01).
Figure 1 also shows OS by BMI category. In multivariable analyses adjusted for the variables detailed above (data not shown),
baseline BMI was a predictor of OS, with a five-unit increase
in BMI corresponding to an 8% increase in the risk of death

Baseline BMI and Tumor and Host Characteristics
BMI was associated with tumor size (P = .004) and patients’
race, age, and menopausal status at registration (all P < .001).
Table 2. Baseline body mass index and distribution of PAM50 subtypes*

BMI category
Underweight
(<18.5 kg/m2)

Normal
(18.5–24.9 kg/m2)

Overweight
(25–29.9 kg/m2)

Obese
(≥30 kg/m2)

Total

Subtype

No. (%)

No. (%)

No. (%)

No. (%)

No. (%)

PAM substudy patients
Basal-like
HER2-enriched
Luminal A
Luminal B

17
5 (29.4)
4 (23.5)
3 (17.6)
5 (29.4)

409
101 (24.7)
81 (19.8)
141 (34.5)
86 (21.0)

409
73 (17.8)
83 (20.3)
140 (34.2)
113 (27.6)

437
105 (24.0)
83 (19.0)
119 (27.2)
130 (29.7)

1272
284 (22.3)
251 (19.7)
403 (31.7)
334 (26.3)

* BMI = body mass index; HER2 = human epidermal growth factor receptor 2.
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0.8
0.6

< 18.5
18.5 − 24.9
25 − 29.9
30+

0.0

Proportion recurrence−free

1.0

A

0.4
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0

2

N = 22
N = 623
N = 628
N = 636
4

Events = 9
Events = 179
Events = 208
Events = 223
6

8

10

12

11
352
329
328

3
87
67
68

Years from study entry
Number at risk
22
621
630
636

19
569
542
555

14
503
471
471

13
451
413
421

12
396
369
376

< 18.5
18.5 − 24.9
25 − 29.9
30+

N = 22
N = 623
N = 628
N = 636

Deaths = 7
Deaths = 151
Deaths = 184
Deaths = 201

1.0

< 18.5
18.5 − 24.9
25 − 29.9
30+

0.6
0.4
0.0
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0.2

Proportion survivng

0.8

B

0

2

4

6

8

10

12

13
382
354
351

3
102
85
75

Years from study entry
< 18.5
18.5 − 24.9
25 − 29.9
30+

Number at risk
22
623
628
636

19
602
589
601

16
546
526
530

15
494
450
465

15
436
405
408

Figure 1. Recurrence-free (A) and overall (B) survival by body mass index. BMI = body mass index.

(adjusted HR = 1.08, 95% CI = 1.01 to 1.14, P = .02). There was
no interaction between cycle length and the prognostic value of
baseline BMI on RFS (P = .41) or on OS (P = .27).

BMI and Outcomes by Estrogen Receptor Status
and PAM50
Multivariable models adjusted for known prognostic factors (as
detailed above) did not demonstrate an interaction between

estrogen receptor status and BMI (linearly modeled) on recurrence-free (P = .87) or overall survival (P = .53). For both estrogen receptor–positive and estrogen receptor–negative patients,
there was an identical increase in the risk of both relapse and
death with increasing BMI.
An exploratory analysis of the prognostic value of baseline
BMI and PAM50 was performed using a multivariable model
adjusting for the factors described above. In the subset with
PAM50 data, BMI remained a statistically significant prognostic

J. A. Ligibel et al. | 6 of 7

Table 3. Observed effect of BMI on recurrence-free survival: results of multivariable proportional hazards model (n = 1845, 32% events)
Variable
BMI
No. nodes†
Tumor size†
Menopause
ER status
Sequence
Dose density

HR comparison

HR (95% CI)

P*

5-unit increase
1: 10
2 cm: 5 cm
Post: pre
Negative: positive
Sequential: concurrent
q 3 wks: q 2 wks

1.08 (1.02 to 1.14)
0.44 (0.37 to 0.52)
0.72 (0.62 to 0.82)
1.11 (0.94 to 1.31)
1.54 (1.31 to 1.82)
1.05 (0.89 to 1.23)
1.21 (1.03 to 1.43)

.01
<.001
<.001
.22
<.001
.57
.02

* P values are from a Wald-type test in the multivariable proportional hazards model. BMI = body mass index; CI = confidence interval; ER = estrogen receptor;
HR = hazard ratio.
† A square root transformation was used in analyses as performed in Citron et al. (2003).
N
PAM50 subset
Luminal A
Luminal B
HER2−enriched
Basal−like

1272
403
334
251
284

HR (95% CI)
1.12 (1.04 to 1.19)
1.23 (1.08 to 1.40)
1.00 (0.87 to 1.16)
1.10 (0.97 to 1.26)
1.11 (0.97 to 1.28)
0.50

0.75

1.00

1.25

1.50

Hazard ratio

factor, with a five-unit increase in BMI resulting in a hazard ratio
of 1.12 (95% CI = 1.04 to 1.19, P = .01) (Figure 2). In the multivariable model, the interaction test between the prognostic effects of
BMI and intrinsic subtype did not reach statistical significance (3
df, P = .15). Within subgroups defined by PAM50, the unadjusted
HR for each five-unit increase in BMI was highest at 1.23 (95%
CI = 1.08 to 1.40) in Luminal A, lowest at 1.00 (95% CI = 0.87 to
1.16) in Luminal B, 1.10 (95% CI = 0.97 to 1.26) in HER2 enriched,
and 1.11 (95% CI = 0.97 to 1.28) in the Basal-like subgroup.

Discussion
In a population of women with early-stage breast cancer treated
with optimal doses of adjuvant chemotherapy, obesity was an
independent prognostic factor for both recurrence-free and overall survival. Each five-unit increase in BMI (for example, increasing from a BMI of 22 mg/m2, which is in the normal range, to a
BMI of 27 kg/m2, in the overweight range) was associated with an
increase in the risk of cancer recurrence and death, or of death
alone, of approximately 8%. Being underweight was also associated with poor prognosis, but these analyses were based on only
a small number of patients; more work is needed to define the
relationship between BMI and outcomes in underweight individuals. Obese patients were more likely to have larger tumors and
to be postmenopausal, but the distributions of tumor grade and
tumor hormone receptor status were similar across weight categories. In contrast, PAM50 subtypes were distributed differently
in obese and nonobese individuals, with Luminal B tumors being
more common and Luminal A tumors less common in obese
individuals. Finally, exploratory analyses did not show an interaction between molecular subtype by PAM50 and the relationship
between increased BMI and RFS, suggesting that obesity related
to poor clinical outcome regardless of tumor subtype.
Our data demonstrating an increased risk of cancer recurrence and mortality in obese individuals with early-stage breast
cancer are consistent with numerous studies reporting a relationship between BMI and cancer outcomes. However, in contrast
to some reports, we found that increased BMI was associated

with an increased risk of breast cancer recurrence and mortality
regardless of hormone receptor status. In addition, exploratory
analyses of the relationship between BMI and outcome in groups
defined by PAM50 subtype suggested that BMI predicted outcomes in patients with Basal-like and HER2-enriched cancers,
providing additional evidence that the relationship between
body weight and breast cancer outcomes was not restricted to
patients with hormone receptor–positive tumors.
Our study is one of the first to provide information regarding the relationship between biologic subtype and BMI in a large
group of patients with early-stage breast cancer. Although the
distribution of hormone receptor–positive and –negative cancers
did not differ by weight category, our findings suggest that obese
patients may have a different distribution of Luminal tumors
as compared with leaner individuals. The higher proportion of
Luminal B tumors could contribute to the poor outcomes seen in
obese individuals, given that these cancers are associated with
a higher risk of cancer recurrence as compared with Luminal
A tumors. This finding needs to be replicated in other studies,
but suggests that the biology of the tumors that obese women
develop might account, at least in part, for the relationship seen
between obesity and outcomes in breast cancer. It is not clear
how this finding will influence the potential benefits of weight
loss after cancer diagnosis in obese women with breast cancer;
randomized trials are needed to evaluate the impact of purposeful weight loss on disease outcomes in women with early breast
cancer overall and by biological subtype.
Our study has limitations that should be noted. Our sample size
was relatively modest, and PAM50 data were only available for a
subset of patients, limiting the power of our analyses; however, our
dataset is larger than that included in any other report on the relationship between biologic subtype and BMI to date. These analyses
should be viewed as hypothesis generating and require further validation. Our analyses were also retrospective and not preplanned.
Although we adjusted these analyses for many known prognostic
factors, it is possible that other factors we have not accounted for
could influence the relationship between BMI and prognosis. We
also lacked information regarding adherence to endocrine therapy,
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Figure 2. Recurrence-free survival by body mass index (BMI) in PAM50 subtypes. Hazard ratios are for a five-unit increase in BMI and displayed with 95% confidence
intervals. The area of the square is proportional to the precision of the estimate. CI = confidence interval; HR = hazard ratio.
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given that the trial focused on the impact of chemotherapy on disease outcomes. Finally, our patient population was largely white,
and thus it is not clear how these findings relate to minority populations, who are often disproportionally affected by obesity. Further
evaluation of the relationship between obesity and breast cancer
outcomes is needed in these populations.
In conclusion, we found an increased risk of breast cancer
recurrence and death in overweight and obese individuals with
newly diagnosed breast cancer taking part in an adjuvant clinical
trial of anthracycline and taxane-based chemotherapy. Obesity
was linked to differences in the distribution of breast cancer
subtypes, with more aggressive Luminal B cancers observed to
be more prevalent in obese individuals, potentially contributing to the poor outcomes seen in this population. Finally, there
was no interaction between tumor subtype and the relationship between body weight and prognosis, suggesting that obesity was predictive of poor outcomes across biological subtypes.
More work is needed to validate our findings regarding biologic
differences between cancers developed by obese and nonobese
individuals, to elucidate the biologic mechanisms by which obesity affects prognosis, and to determine whether weight loss
after breast cancer diagnosis can alleviate the inferior prognosis
experienced by obese individuals with breast cancer.
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